{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000016","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.244742+00:00","generated_at":"2026-05-23T19:33:24.775540+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iBio reports IBIO-600 NHP half-life up to 52 days; Activin E antibody shows 34% weight loss with semaglutide","bullets":["IBIO-600 NHP half-life 40-52 days; estimated human half-life up to 130 days, enabling once every 3-6 month dosing.","IBIO-600 promoted dose-dependent lean mass increase (3.1% low-dose, 5.1% high-dose) and fat reduction in NHPs after 8 weeks.","Activin E antibody monotherapy in obese mice: 4% weight loss, 18% total body fat reduction vs placebo after 2 weeks.","Activin E antibody combined with semaglutide: 34% total weight loss, 72% fat reduction – synergistic beyond GLP-1 alone.","iBio on track for IBIO-600 regulatory submission in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000016","json":"https://secwatch.observer/filing/0001420720-25-000016.json","markdown":"https://secwatch.observer/filing/0001420720-25-000016.md","text":"https://secwatch.observer/filing/0001420720-25-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000016/0001420720-25-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000016/ibio-20250407x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:33:24.775540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}